Plain-English translation of NCT07049653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is tracking the safety of a medication called anifrolumab in pregnant people with lupus (a serious autoimmune disease). Researchers want to understand whether anifrolumab affects pregnancy outcomes, birth defects, or infant health in the first year of life by comparing pregnancies in people who took this medication with pregnancies in people who took other standard lupus treatments.
While lupus requires ongoing treatment during pregnancy, doctors need clear information about whether specific medications like this one are safe for developing babies. This study will help fill that gap so doctors and pregnant people with lupus can make informed treatment decisions together.
You likely qualify if…
You likely don't qualify if…
This is not a traditional clinical trial where you take a new drug — instead, researchers will review your existing medical records from databases to track what happened during your pregnancy and your baby's first year of life. You will not need to attend special visits or change your current lupus treatment. The study simply observes and compares real-world pregnancy outcomes between people who took this medication and those who took other lupus treatments.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States
AstraZeneca
Collaborators
IQVIA Pty Ltd
Enrollment target
~500 participants
Started
June 2026
Primary completion
December 2030
Age range
18 Years – 130 Years
Sex
Female only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
AstraZeneca
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.